Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …

Can a chronic condition like type 1 diabetes be slowed before it fully develops? Recent long-term studies suggest that preventing or delaying type 1 diabetes may be closer to reality than once believed. In fact, emerging immunotherapy data is changing how clinicians view early-stage disease and the opportunity to intervene …

Managing hyperglycemia in oncology patients is becoming a critical part of cancer care, especially as newer therapies affect glucose metabolism. Have you ever wondered why patients with no history of diabetes suddenly develop high blood sugar during treatment? This growing challenge highlights the need for structured, practical approaches. In this …

In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …

Why do some patients respond dramatically to GLP-1 therapies while others see little benefit? This question is becoming more relevant as GLP-1 receptor agonists gain widespread use in diabetes and weight management. Increasingly, clinicians are encountering cases of reduced response to GLP-1 therapies, where expected glycemic or weight outcomes fail …

The choice between oral GLP-1 and injectable therapy is quickly becoming a central question in type 2 diabetes care. With the arrival of oral semaglutide, clinicians now have more flexibility than ever. But how do you decide between a daily pill and a weekly injection? While both options target the …

What happens when a patient does not fit the textbook definition of diabetes care? In real-world practice, uncertainty in diabetes care is more common than many clinicians expect. While guidelines provide a strong foundation, they cannot cover every clinical scenario. As a result, providers often face complex decisions without clear …

Care fragmentation in GLP-1 therapy is becoming a growing concern as more patients receive prescriptions from multiple providers. As GLP-1 receptor agonists gain popularity for diabetes and weight management, care often spans endocrinologists, primary care physicians, telehealth platforms, and retail clinics. But what happens when these providers are not aligned? …

The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …

As GLP-1 receptor agonists become a cornerstone of diabetes care, clinicians are rethinking how often patients on GLP-1 therapy need follow-up visits. These therapies often deliver improved glycemic control, weight loss, and cardiovascular benefits. However, does this stability mean fewer clinic visits, or does it require closer monitoring in new …